Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.
Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan HM, Swinderman J, Wilson C, Zhu J, Das R, Nguyen M, Loehr A, Golsorkhi T, Simmons A, Abida W, Chinnaiyan AM, Arkin MR, Small EJ, Quigley DA, Yang L, Kim M, Ashworth A, Feng FY. Chou J, et al. Among authors: egusa ea. Clin Cancer Res. 2024 Dec 2;30(23):5445-5458. doi: 10.1158/1078-0432.CCR-23-3785. Clin Cancer Res. 2024. PMID: 39321214
Large tandem duplications in cancer result from transcription and DNA replication collisions.
Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L. Yang Y, et al. Among authors: egusa ea. medRxiv [Preprint]. 2024 Jan 10:2023.05.17.23290140. doi: 10.1101/2023.05.17.23290140. medRxiv. 2024. Update in: Nat Cancer. 2024 Dec;5(12):1885-1901. doi: 10.1038/s43018-024-00848-4 PMID: 38260434 Free PMC article. Updated. Preprint.
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, Peter R, Ali U, Meher N, Wadhwa A, Dhrona S, Dasari C, Beckford-Vera D, Su Y, Tang R, Zhang L, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Chou J, Liu B, Flavell RR. Bidkar AP, et al. Among authors: egusa ea. Clin Cancer Res. 2023 May 15;29(10):1916-1928. doi: 10.1158/1078-0432.CCR-22-3291. Clin Cancer Res. 2023. PMID: 36917693 Free PMC article.
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. Chou J, et al. Among authors: egusa ea. Cancer Res. 2023 Jan 18;83(2):301-315. doi: 10.1158/0008-5472.CAN-22-1433. Cancer Res. 2023. PMID: 36351060 Free PMC article.
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. Zhao N, et al. Among authors: egusa ea. Clin Cancer Res. 2022 Jul 15;28(14):3066-3075. doi: 10.1158/1078-0432.CCR-21-3858. Clin Cancer Res. 2022. PMID: 35604681 Free PMC article.
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. Chou J, et al. Among authors: egusa ea. Eur Urol Oncol. 2022 Dec;5(6):714-718. doi: 10.1016/j.euo.2021.11.005. Epub 2022 Feb 23. Eur Urol Oncol. 2022. PMID: 35216942 Free PMC article.
An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.
Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, Small EJ, Ashworth A, Feng FY, Gilbert LA. Das R, et al. Among authors: egusa ea. Nat Commun. 2021 Jul 29;12(1):4601. doi: 10.1038/s41467-021-24919-7. Nat Commun. 2021. PMID: 34326322 Free PMC article.
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. Chu CE, et al. Among authors: egusa ea. Clin Cancer Res. 2021 Sep 15;27(18):5123-5130. doi: 10.1158/1078-0432.CCR-20-4175. Epub 2021 Jun 9. Clin Cancer Res. 2021. PMID: 34108177 Free PMC article.
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. Wang S, et al. Among authors: egusa ea. Clin Cancer Res. 2021 Mar 1;27(5):1305-1315. doi: 10.1158/1078-0432.CCR-20-3310. Epub 2020 Dec 8. Clin Cancer Res. 2021. PMID: 33293372 Free PMC article.
11 results